Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TALENTACE
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- NCT04712643 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Deep
We haven't built an HCP commentary report on TALENTACE (atezolizumab and becavizumab in Hepatocellular Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TALENTACE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| YouTube | 6 | |
| Podcasts | 5 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Atezolizumab; Becavizumab; Transarterial chemoembolization (TACE)
- Arms
- Arm A: atezolizumab + bevacizumab + TACE · Experimental
- Arm B: TACE alone · Active comparator
- Enrollment
- 342
- Primary outcomes
- TACE Progression-Free Survival (TACE PFS) as Determined by Investigator
- Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche
- Start
- Mar 12, 2021
- Primary completion
- Feb 1, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT04712643 · updated Oct 26, 2026
Publications
linked from the registry- Kudo M, Ogasawara S, Liu R, Gu S, Wang K, Zhao M, Hu H, Liu Z, Lin K, Liu J, Lin Z, Zhang Y, Peng T, Song J, Ueno M, Zhu J, Bai L, Tong L, Shi Y, Han G, Dong J. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 Aug 25:S2468-1253(26)00212-8. doi: 10.1016/S2468-1253(26)00212-8. Online ahead of print. PubMed 42641632